Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
334
datasets available to search
ShareScore release 0.9.0
Dataset results
334 results for “targeted cancer therapy”
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients with Metastatic Clear Cell Renal Cancer
ClinicalTrials.gov study NCT06059014. IPD Sharing: NO. Countries: 1. Publications: 1.
Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer
ClinicalTrials.gov study NCT02305043. IPD Sharing: Not stated. Countries: 1. Publications: 3.
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
ClinicalTrials.gov study NCT02142036. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
ClinicalTrials.gov study NCT07287904. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Novel Therapy Target in Metastatic Prostate Cancer
ClinicalTrials.gov study NCT05577689. IPD Sharing: NO. Countries: 1. Publications: 6.
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
ClinicalTrials.gov study NCT02753686. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies
ClinicalTrials.gov study NCT06254196. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT03178552. IPD Sharing: YES. Countries: 27. Publications: 3.
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
ClinicalTrials.gov study NCT03699449. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
ClinicalTrials.gov study NCT03792529. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
ClinicalTrials.gov study NCT05165602. IPD Sharing: NO. Countries: 1. Publications: 14.
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
ClinicalTrials.gov study NCT00933517. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)
ClinicalTrials.gov study NCT03084757. IPD Sharing: YES. Countries: 1. Publications: 1.
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
ClinicalTrials.gov study NCT06575127. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.
Data from: Probabilistic interfractional motion carbon ion radiation therapy dose distribution for prostate cancer shows rectum sparing with moderate target coverage degradation
Open the record for dataset details and reuse information.
Data from: Development and evaluation of a fluorescent antibody-drug conjugate for molecular imaging and targeted therapy of pancreatic cancer
Antibodies are widely available and cost-effective research tools in life science, and antibody conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer. Significant advances in site-specific antibody labeling technologies have enabled the production of highly characterized and homogenous conjugates for biomedical purposes, and some recent studies have utilized site-specific labeling to synthesize bifunctional antibody conjugates with both imaging and drug delivery properties. While these advances are important for the clinical safety and efficacy of such biologics, these techniques can also be difficult, expensive, and time-consuming. Furthermore, antibody-drug conjugates (ADCs) used for tumor treatment generally remain distinct from conjugates used for diagnosis. Thus, there exists a need to develop simple dual-labeling methods for efficient therapeutic and diagnostic evaluation of antibody conjugates in pre-clinical model systems. Here, we present a rapid and simple method utilizing commercially available reagents for synthesizing a dual-labeled fluorescent ADC. Further, we demonstrate the fluorescent ADC's utility for simultaneous targeted therapy and molecular imaging of cancer both in vitro and in vivo. Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified (PEGylated) fluorophore (DyLight™ 680-4xPEG). Using in vitro systems, we demonstrate that this fluorescent ADC selectively binds a CEA-positive pancreatic cancer cell line (BxPC-3) in immunofluorescent staining and flow cytometry, exhibits efficient internalization kinetics, and is cytotoxic. Model studies using a xenograft of BxPC-3 cells in athymic mice also show the fluorescent ADC's efficacy in detecting tumors in vivo and inhibiting tumor growth more effectively than equimolar amounts of unconjugated drug. Overall, our results demonstrate that non-selective, amine-targeting chemistry is an effective dual-labeling method for synthesizing and evaluating a bifunctional fluorescent antibody-drug conjugate, allowing concurrent detection, monitoring and treatment of cancer.
Targeted therapy of BRCA2 hypermethylation of breast cancer tumorigenesis in carrier females: A Review
Open the record for dataset details and reuse information.
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
ClinicalTrials.gov study NCT00570232. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
ClinicalTrials.gov study NCT02949843. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
ClinicalTrials.gov study NCT06623396. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.